AstraZeneca plc (NYSE:AZN) has earned an average rating of “Hold” from the eighteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $43.60.

AZN has been the topic of several recent research reports. Goldman Sachs Group reiterated a “sell” rating on shares of AstraZeneca in a research report on Friday, November 16th. Credit Suisse Group reiterated a “buy” rating on shares of AstraZeneca in a research report on Sunday, December 9th. HSBC reiterated a “sell” rating on shares of AstraZeneca in a research report on Monday, November 12th. UBS Group reiterated a “hold” rating on shares of AstraZeneca in a research report on Monday, November 19th. Finally, Deutsche Bank reiterated a “buy” rating on shares of AstraZeneca in a research report on Monday, November 12th.

AZN stock opened at $39.15 on Tuesday. The company has a current ratio of 0.86, a quick ratio of 0.66 and a debt-to-equity ratio of 1.36. The firm has a market cap of $99.16 billion, a price-to-earnings ratio of 9.15, a PEG ratio of 2.20 and a beta of 0.55. AstraZeneca has a fifty-two week low of $32.69 and a fifty-two week high of $41.78.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.38. The firm had revenue of $5.34 billion for the quarter, compared to analysts’ expectations of $5.26 billion. AstraZeneca had a return on equity of 27.32% and a net margin of 11.29%. The company’s quarterly revenue was down 14.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.12 EPS. As a group, equities analysts expect that AstraZeneca will post 1.68 EPS for the current fiscal year.

In related news, major shareholder Plc Astrazeneca bought 600,000 shares of AstraZeneca stock in a transaction dated Monday, October 22nd. The shares were bought at an average cost of $5.00 per share, with a total value of $3,000,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Primecap Management Co. CA boosted its stake in AstraZeneca by 4.5% in the third quarter. Primecap Management Co. CA now owns 55,399,286 shares of the company’s stock valued at $2,192,150,000 after buying an additional 2,364,013 shares in the last quarter. Jennison Associates LLC boosted its stake in AstraZeneca by 106.2% in the third quarter. Jennison Associates LLC now owns 39,744,304 shares of the company’s stock valued at $1,572,682,000 after buying an additional 20,470,137 shares in the last quarter. FMR LLC boosted its stake in AstraZeneca by 74.5% in the third quarter. FMR LLC now owns 35,325,790 shares of the company’s stock valued at $1,397,841,000 after buying an additional 15,082,609 shares in the last quarter. Fisher Asset Management LLC boosted its stake in AstraZeneca by 3.3% in the third quarter. Fisher Asset Management LLC now owns 13,516,724 shares of the company’s stock valued at $534,857,000 after buying an additional 436,783 shares in the last quarter. Finally, Capital International Investors boosted its stake in AstraZeneca by 3.4% in the third quarter. Capital International Investors now owns 9,752,587 shares of the company’s stock valued at $385,910,000 after buying an additional 319,416 shares in the last quarter. 17.18% of the stock is currently owned by institutional investors.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: What are the most popular ETFs

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.